中药治疗非酒精性脂肪性肝炎肝纤维化的作用机制

杜 田田¹, 安 纪红²
1、内蒙古医科大学
2、内蒙古自治区人民医院 · 感染科

摘要

目的：非酒精性脂肪性肝病（NAFLD）是全球最普遍的肝病，影响 20-25% 的成年人口。在 25% 的患者中，NAFLD 进
展为非酒精性脂肪性肝炎（NASH），这增加了肝硬化，肝衰竭和肝细胞癌发展的风险。在 NASH 患者中，肝纤维化是死亡率
的主要决定因素。早期的肝纤维化经过规范有效的抗肝纤治疗后可以逆转，若不及时给予干预，肝纤维化的程度将逐渐加
重并进展为肝硬化，最终发展为肝细胞癌。因此，积极防治肝纤维化具有重要意义。然而目前西医对于肝纤维化的治疗比
较单一、局限，缺乏疗效确切且公认的抗纤维化药物，现有的治疗手段无法满足医疗需求。随着国内外学者的研究深入，
中草药成为了逆转肝纤维化和抗纤维化进展的热点，并发现了多层次、多靶点、多途径的优势。

关键词

非酒精性脂肪性肝炎；肝纤维化；中药；作用机制

参考

[1] V. Ajmera, P. Belt, L.A. Wilson, R.M. Gill, R. Loomba, D.E. Kleiner, B. A. Neuschwander-Tetri, N. Terrault, N. Nonalcoholic Steatohepatitis Clinical Research, Am1ong patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis,Clin[J]. Gastroenterol. Hepatol. 2018,16 (9): 1511–1520, e5.

[2] D.J. van der Windt, V. Sud, H. Zhang, A. Tsung, H. Huang, The effects of physical exercise on fatty liver disease[J]. Gene Expr. 2018,18 (2):89–101.

[3] S. Ikramuddin, J. Korner, W.J. Lee, A.J. Thomas, J.E. Connett, J.P. Bantle, D. B. Leslie, Q. Wang, W.B. Inabnet, R.W. Jeffery, K. Chong, L.M. Chuang, M. D. Jensen, A. Vella, L. Ahmed, K. Belani, C[J]. Billington, Lifestyle intervention and medical management with vs without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the diabetes surgery study, JAMA

2018,319(3):266–278.

[4] I. Mikolasevic, T. Filipec-Kanizaj, M. Mijic, I. Jakopcic, S. Milic, I. Hrstic, N. Sobocan, D. Stimac, P. Burra, Nonalcoholic fatty liver disease and liver transplantation – where do we stand? World J. Gastroenterol.2018 ,24 (14):1491–1506.

[5] M. Romero-G´omez, S. Zelber-Sagi, M. Trenell, Treatment of NAFLD with diet,physical activity and exercise[J]. Hepatol. 2017,67(4):829–846.

[6] N . A l k h o u r i , A . S c o t t , A n u p d a t e o n t h e pharmacological treatment of nonalcoholic fatty liver disease: beyond lifestyle modifications, Clin. Liver Dis.2018,11(4):82–86.

[7] R. Vuppalanchi, M. Noureddin, N. Alkhouri, A[J]. Sanyal, Therapeutic pipeline in nonalcoholic steatohepatitis, Nat. Rev. Gastroenterol. Hepatol.2021.18(6):373–392.

[8] X. Zheng, M.G. Zhao, C.H. Jiang, X.P. Sheng, H.M. Yang, Y. Liu, X.M. Yao, J. Zhang, Z.Q. Yin, Triterpenic acidsenriched fraction from Cyclocarya paliurus attenuates insulin resistance and hepatic steatosis via PI3K/Akt/GSK3β pathway, Phytomedicine 2020.

[9] Y. Liu, W. Xu, T. Zhai, J. You, Y. Chen, Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLARJNK pathway, Acta Pharm. Sin. B 2019:745–757.

[10] J. Zhang, H. Zhang, X. Deng, N. Zhang, B. Liu, S. Xin, G. Li, K. Xu, Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice, Life Sci.

2018:46–54.

[11] D. Yan, Y.Y. Wei, X.M. Li, X.C. Sun, Z. Wang, H.A. Aisa, PFP alleviates nonalcoholic steatohepatitis fatty liver in both Apo E(-/-) mice and Changliver cell[S], Am. J. Transl. Res. 9 (6) (2017) 3073–3083.

[12] S.H. Ahn, K.P. Lee, K. Kim, J.Y. Choi, S.Y. Park, J.H. Cheon, Dansameum regulates hepatic lipogenesis and inflammation in vitro and in vivo, Food Sci. Biotechnol.2019, 28(5):1543–1551.

[13] T.H. Xie, J.X. Li, T.Y. Mao, Y. Guo, C. Chen, Y.F. Han, X. Tan, R.H. Chen, An ErChen and YinChen decoction ameliorates high-fat-induced nonalcoholic steatohepatitis in rats by regulating JNK1 Signaling pathway, Evid. Based Complement Altern. Med, 2017.

[14] N. Xu, X. Wu, H.J. Luo, F.F. Xu, Q.H. Huang, J.Z. Wu, Y.X. Gan, M.Y. Li, Z.Q. Lai, H.R. Lin, J.N. Chen, Z.R. Su, W.P. Ai, Y.H. Liu, Patchouli oil attenuates high fat diet-induced non-alcoholic hepatic steatosis, Planta Med,2020,86(4):255–266.

[15] C. Ho, Y. Gao, D. Zheng, Y. Liu, S. Shan, B. Fang, Y. Zhao, D. Song, Y. Zhang, Q. Li, Alisol A attenuates high-fat-diet-induced obesity and metabolic disorders via the AMPK/ACC/SREBP-1c pathway, J. Cell Mol. Med. 2019,23 (8):5108–5118.

[16] C. Wu, M. Jing, L. Yang, L. Jin, Y. Ding, J. Lu, Q. Cao, Y. Jiang, Alisol A 24-acetate ameliorates nonalcoholicsteatohepatitis by inhibiting oxidative stress and stimulating autophagy through the AMPK/mTOR pathway, Chem. Biol. Inter,2018:111–119.

[17] J. Liu, R. Sun, Protective effect of Xiaochaihu Decoction on non-alcoholic steatohepatitis model mice, Chin. Tradit. Herb. Drugs ,2020,51 (14):3708–3716.

[18] S. Gao, T. Wang, X. Huang, Y. Jin, Y. Xu, Y. Xi, J. Zhang, Y. Luo, H. Xu, H. Guo, D. Ke, J. Wang, Exploring the protective effect of Modified Xiaochaihu Decoction against hepatic steatosis and inflammation by network pharmacology and validation in ageing rats, Chin. Med, 2020.

[19] X.W. Gong, Y.J. Xu, Q.H. Yang, Y.J. Liang, Y.P. Zhang, G.L. Wang, Y.Y. Li, Effect of soothing Gan (Liver) and invigorating Pi (Spleen) recipes on TLR4-p38 MAPK pathway in kupffer cells of non-alcoholic steatohepatitis rats, Chin. J. Integr. Med. 2019,25(3):216–224.

[20] H.F. Lu, Y.H. Lai, H.C. Huang, I.J. Lee, L.C. Lin, H.K. Liu, H.H. Tien, C. Huang, Ginseng-plus-Bai-Hu-Tang ameliorates diet-induced obesity, hepatic steatosis, and insulin resistance in mice, J. Ginseng Res. 2020,44(2):238–246.

[21] M.T. Liu, Y.J. Huang, T.Y. Zhang, L.B. Tan, X.F. Lu, J. Qin, Lingguizhugan decoction attenuates diet-induced obesity and hepatosteatosis via gut microbiota, World J. Gastroenterol.

2019,25(27):3590–3606.

[22] H. Xu, G.F. Chen, Y.S. Ma, H.W. Zhang, Y. Zhou, G.H. Liu, D.Y. Chen, J. Ping, Y. H. Liu, X. Mou, D. Fu, Hepatic proteomic changes and Sirt1/AMPK signaling activation by oxymatrine treatment in rats with non-alcoholic steatosis, Front[J].Pharmacol,. 2020.

[23] Y. Yao, Ginsenosides reduce body weight and ameliorate hepatic steatosis in high fat diet‑induced obese mice via endoplasmic reticulum stress and p-STAT3/ STAT3 signaling, Mol. Med. Rep. 2020,21(3):1059–1070.

[24] T. Zhai, W. Xu, Y. Liu, K. Qian, Y. Xiong, Y. Chen, Honokiol alleviates methionine-choline deficient dietinduced hepatic steatosis and oxidative stress in C57BL/6 mice by regulating CFLAR-JNK pathway, Oxid. Med. Cell

Longev,2020.

[25] T. Lan, Y. Yu, J. Zhang, H. Li, Q. Weng, S. Jiang, S. Tian, T. Xu, S. Hu, G. Yang, Y. Zhang, W. Wang, L. Wang, Q. Zhu, X. Rong, J. Guo, Cordycepin ameliorates nonalcoholic

steatohepatitis via activation of AMP-activated protein kinase signaling pathway, Hepatology 2021.

[26] X. Tian, Q. Ru, Q. Xiong, R. Wen, Y. Chen, Catalpol attenuates hepatic steatosis by regulating lipid metabolism via AMP-activated protein kinase activation, Biomed. Res. Int.2020.

[27] H.U. Fei-Fei, H. Zhan-Xia, Z. Shao-Bo, S. Yu-Chen, J.I. Li-Li, Study on improvement provided by water extracts of Polygoni Multiflori Radix and Polygoni Multiflori Radix Praeparata on non-alcoholic steatohepatitis in mice induced by MCD, Zhongguo Zhong Yao Za Zhi,2020,45(19):4732–4739.

[28] Q. Meng, X.P. Duan, C.Y. Wang, Z.H. Liu, P.Y. Sun, X.K. Huo, H.J. Sun, J.Y. Peng, K.X. Liu, Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation, Acta Pharmacol. Sin. 2017,38(1):69–79.

[29] C.H. Zhang, Q. Xiao, J.Q. Sheng, T.T. Liu, Y.Q. Cao, Y.N. Xue, M. Shi, Z. Cao, L. F. Zhou, X.Q. Luo, K.Z. Deng, C. Chen, Gegen qinlian decoction abates nonalcoholic steatohepatitis associated liver injuries via anti-oxidative stress and anti-inflammatory response involved inhibition of toll-like receptor 4 signaling pathways, Biomed. Pharmacother.2020.

[30] Y. Zhang, X. Zhu, D. Zheng, Y. Yin, M. Peng, J. Wang, Effects of Qutan Huoxue formula on the SOCS1/TLR4 signaling pathway in NASH model mice, Evid. Based Complement Altern. Med. 2020.

[31] J. Xiao, F. Wang, E.C. Liong, K.F. So, G.L. Tipoe, Lycium barbarum polysaccharides improve hepatic injury through NFkappa-B and NLRP3/6 pathways in a methionine choline deficient diet steatohepatitis mouse model, Int.J. Biol. Macromol. 2018,120(PtB):1480–1489.

[32] H. Jeong, J.W. Kim, M.S. Yang, C. Park, J.H. Kim, C.W. Lim, B. Kim, Beneficial effects of Korean red ginseng in the progression of non-alcoholic steatohepatitis via FABP4 modulation, Am. J. Chin. Med. 2018.

[33] I.C. Yen, J.C. Lin, Y. Chen, Q.W. Tu, S.Y. Lee, Antrodia Cinnamomea attenuates non-alcoholic steatohepatitis by suppressing NLRP3 inflammasome activation in vitro and in vivo, Am. J. Chin. Med. 2020,48(8):1859–1874.

[34] Y. Ma, T. Han, S. Yang, C. Yu, X. Shi, Y. Wu, Efficacy of Cigu Xiaozhi pill on non- alcoholic steatohepatitis-associated lipoapoptosis through stress-activated c-Jun N-terminal kinase signalling pathway, J. Tradit. Chin. Med. 2021,41(1):79–88.

[35] X. Shu, M. Wang, H. Xu, Y. Liu, J. Huang, Z. Yao, L. Zhang, Extracts of Salvia-Nelumbinis naturalis ameliorate nonalcoholic steatohepatitis via inhibiting gut- derived endotoxin mediated TLR4/NF-κB activation, Evid. Based Complement Altern. Med. 2017.

[36] L. Xiao, S. Liang, L. Ge, S. Qiu, H. Wan, S. Wu, J. Fei, S. Peng, X. Zeng, Si-Wei- Qing-Gan-Tang improves nonalcoholic steatohepatitis by modulating the nuclear factor-κB signal pathway and autophagy inmethionineand choline deficient diet-fed rats, Front. Pharmacol.2020.

[37] A.B. Marcher, S.M. Bendixen, M.K. Terkelsen, S.S. Hohmann, M.H. Hansen, B. D. Larsen, S. Mandrup, H. Dimke, S. Detlefsen, K. Ravnskjaer, Transcriptional regulation of Hepatic Stellate Cell activation in NASH, Sci. Rep. 2019.

[38] I. Milosevic, A. Vujovic, A. Barac, M. Djelic, M.Korac, A. Radovanovic Spurnic, I. Gmizic, O. Stevanovic, V. Djordjevic, N. Lekic, E. Russo, A. Amedei, Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature, Int. J. Mol. Sci.2019(20):2.

[39] Y. Wang, Y.L. Tai, D. Zhao, Y. Zhang, J. Yan, G. Kakiyama, X. Wang, E.C. Gurley, J. Liu, J. Liu, J. Liu, G. Lai, P.B. Hylemon, W.M. Pandak, W. Chen, H. Zhou, Berberine prevents disease progression of nonalcoholic steatohepatitis through modulating multiple pathways, Cells 2021.

[40] N. Jia, X. Lin, S. Ma, S. Ge, S. Mu, C. Yang, S. Shi, L. Gao, J. Xu, T. Bo, J. Zhao Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in Gynostemma pentaphylla (Thunb.) Makino treated mice, Nutr. Metab.2018.

[41] M.J. Gong, C.Y. Zhu, Z.J. Zou, B. Han, P. Huang, Therapeutic potential of puerarin against methioninecholine-deficient diet-induced non-alcoholic steatohepatitis determined by combination of (1)H NMR spectroscopy-based metabonomics and 16S rRNA gene sequencing, J. Pharm. Biomed. Anal. 2021.

[42] H. Li, Y. Xi, X. Xin, H. Tian, Y. Hu, Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis, Biomed. Pharmacother. 2020.

[43] Y. Hong, B. Li, N. Zheng, G. Wu, J. Ma, X. Tao, L. Chen, J. Zhong, L. Sheng, H. Li, Integrated metagenomic and metabolomic analyses of the effect of Astragalus Polysaccharides on alleviating high-fat diet-induced metabolic disorders, Front. Pharmacol.2020.

[44] J. Zheng, L. Zhu, B. Hu, X. Zou, H. Hu, Z. Zhang, N. Jiang, J. Ma, H. Yang, H. Liu, 1-Deoxynojirimycin improves high fat diet-induced nonalcoholic steatohepatitis by restoring gut dysbiosis, J. Nutr. Biochem,2019.

[45] Y. Guo, P.H. Ding, L.J. Liu, L. Shi, T.Y. Mao, J.X. Li, Y.L. Wang, Gegen qinlian decoction attenuates high-fat dietinduced steatohepatitis in rats via gut microbiota, Evid. Based

Complement Altern. Med. 2018.

[46] J.E. Lee, S.M. Lee, J. Jung, Integrated omics analysis unraveled the microbiome- mediated effects of Yijin-Tang on hepatosteatosis and insulin resistance in obese mouse, Phytomedicine 2020.

[47] J. Leng, F. Huang, Y. Hai, H. Tian, W. Liu, Y. Fang, Y. Hu, J. Peng, Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway, Phytomedicine 2020.

[48] J.H. Peng, J. Leng, H.J. Tian, T. Yang, Y. Fang, Q. Feng, Y. Zhao, Y.Y. Hu, Geniposide and chlorogenic acid combination ameliorates non-alcoholic steatohepatitis involving the protection on the gut barrier function in mouse induced by high-fat diet, Front. Pharmacol. 2018.

[49] Q. Li, M. Li, F. Li, W. Zhou, Y. Dang, L. Zhang, G. Ji, Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice, J. Ethnopharmacol. 2020.